Scientists have discovered two compounds in a single molecule that attacks a pair of proteins closely associated with development of Parkinson’s disease (PD).
This new dual inhibitor (compound 6) attacks two enzymes—the leucine-rich repeat kinase 2 (LRRK2) and the c-jun-N-terminal kinase (JNK). Genetic testing of several thousand PD patients has shown that mutations in the LRRK2 gene increase the risk of PD, while JNK has been shown to play an important role in neuron survival in a range of neurodegenerative diseases. Further work is needed to see if dual JNK and LRRK2 inhibition will have added or synergistic efficacy in protecting against neurodegeneration in PD.
More info: http://www.scripps.edu/news/press/2013/20130620lograsso.html
No comments:
Post a Comment